Common TitlePROUD
Official Title Pre-exposure Option for Reducing HIV in the UK: an Open-label Randomisation to Immediate or Deferred Daily Truvada for HIV Negative Gay Men.(PROUD)
Phase Phase IV
ClinicalTrials.gov NCT02065986
Treatments
Tenofovir DF-Emtricitabine
Tenofovir DF-Emtricitabine
Tradename:Truvada and Multiple GenericsOther Names:TDF-FTC, Tenofovir disoproxil fumarate-EmtricitabineClass:Nucleoside Reverse Transcriptase Inhibitors (NRTI)Categories PREP
Funding
IndustryGilead Sciences
Non-IndustryMedical Research Council (MRC)
References
- Dolling DI, Desai M, McOwan A, et al. An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. Trials. 2016;17:163.
- McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53-60.